A PHASE 2, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF RUXOLITINIB CREAM IN PARTICIPANTS WITH LICHEN SCLEROSUS

Registry ID

INCB 18424-220

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

INCYTE CORPORATION

Start date

2024-01-31

Completion date

2024-08-01

Last update

2022-10-25

Conditions

• LICHEN SCLEROSUS

Related clinical trials

• A PHASE 3, DOUBLE-BLINDED, VEHICLE-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF TWICE DAILY DELGOCITINIB CREAM IN ADULT PARTICIPANTS WITH LICHEN SCLEROSUS DURING A 12-WEEK INITIAL TREATMENT PERIOD FOLLOWED BY A 40-WEEK CONTINUATION TREATMENT PERIOD

View on source registry